



Diagnostic and Therapeutic Monitoring for Neurometabolic Disorders

Guest Editors:

Dr. Curtis Coughlin

Center for Bioethics and
Humanities, Department of
Pediatrics, University of Colorado
Anschutz Medical Campus,
Aurora, CO 80045, USA

Dr. J.J.M. (Judith) Jans

Center for Molecular Medicine,
University Medical Center
Utrecht, Utrecht, The
Netherlands

Deadline for manuscript
submissions:

closed (15 December 2023)


Message from the Guest Editors

Neurometabolic disorders are a heterogeneous group of conditions that result in neurological disease sequelae, ranging from developmental delays to complex movement disorders and epilepsy. Diagnostic biomarkers are needed for many of these rare conditions, where clinical diagnosis may go unrecognized. Neurometabolic disorders are traditionally thought of as genetic conditions that result in the accumulation of abnormal metabolites which are often claimed to be neurotoxic. A growing number of therapeutic strategies have aimed to reduce these accumulating metabolites. Biomarkers which can augment genotype–phenotype correlations are critical to determine which patients benefit from treatment. Importantly, biomarkers associated with therapeutic monitoring are often lacking clinical trial endpoints.

We welcome proposals on, but not limited to, the following topics:

- Targeted and untargeted metabolomics in neurometabolic disorders;
- Biomarker discovery and validation for the diagnosis of neurometabolic disorders;
- Genotype–phenotype correlations with biomarkers in patients with neurometabolic disorders;
- Therapeutic monitoring for patients with neurometabolic disorders.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy
2. Formerly Professor of Internal Medicine, School of Specialization of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Biochemistry and Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

Contact Us

Metabolites Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/metabolites
metabolites@mdpi.com
X@MetabolitesMDPI